Top execs bicker over Sanofi’s plan to unload $8B portfolio of old drugs

Arlene Weintraub Back in April, Sanofi CEO Chris Viehbacher said he planned to sell off some of the company's mature products to make room for higher-value "bolt-on" acquisitions. ...

New wave of HER2 meds to fuel huge leap in breast cancer market

Carly Helfand HER2-positive breast cancer treatments already do pretty well for themselves, with Roche's Herceptin taking the No. 8 spot last year on the world's list of best-selling ...

Karolinska Development’s CEO leaves, Erytech hits PhIII endpoints, VBL belatedly nails IPO

Nick Paul Taylor Welcome to the latest edition of our weekly EuroBiotech Report. FierceBiotech News

Salix calls it quits on an inversion over mounting political pressure

Damian Garde Specialty drugmaker Salix Pharmaceuticals is backing out of a $ 2.7 billion deal that would have given it an Irish domicile–and thus a lower tax rate–in the ...

Merck’s Gardasil successor could block 90% of cervical cancers–but first, uptake has to improve

Carly Helfand According to new research, Merck's investigational, 9-valent HPV vaccine has the potential to block about 90% of invasive cervical cancer cases worldwide. But realizing ...

Baxter backs Rockwell with a $45M hemodialysis deal

Damian Garde Kidney drug developer Rockwell Medical picked up a big co-sign from a leader in the space, signing a deal with Baxter International that will help pay the way for its late-stage ...

NICE nixes Roche’s new leukemia drug Gazyvaro despite discount offer

Arlene Weintraub Roche just can't win with the U.K.'s drug price watchdog, the National Institute for Health and Care Excellence (NICE). In August, the agency decided the company's ...

Jason Rhodes joins Atlas Venture investing team

Alok Saboo FierceBiotech News

Salix drops Cosmo buy, opting to talk takeover with Actavis

Carly Helfand Chalk up a victory for the U.S. Treasury Department, whose new rules put the kibosh on Salix Pharmaceuticals' tax inversion deal for Cosmo's Irish unit. Instead, ...

Ascension hospitals bar Genentech reps after cancer drug distribution switch

Tracy Staton One hospital chain has struck back at Roche's Genentech unit for switching its top 3 cancer treatments to specialty distributors. Ascension Health, a Roman Catholic-based ...

Dermira pulls off a $125M IPO as biotechs wax and wane on Wall Street

Damian Garde Skin treatment developer Dermira came through with a top-of-the-range IPO, banking $ 125 million to support its pipeline and charting a rare success in the increasingly ...

Add Arbor Pharma to your shopping list: It’s on the block for $1B-plus

Carly Helfand It's a good time to be a specialty drugmaker–especially one looking to sell itself. And that's the position Arbor Pharmaceuticals is reportedly in right ...
Page 5 of 6« First...23456
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS